secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0001558370-22-006206
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics Q1 cash $76.5M; Phase 3 uproleselan OS events trigger now mid-2023; workforce cut 20%
--------------------------------------------------------------------------------

- Cash and cash equivalents $76.5M at March 31, 2022, down from $90.3M at Dec 31, 2021.
- Phase 3 uproleselan trial in relapsed/refractory AML expects OS events trigger mid-2023, top line data shortly after.
- IND-enabling studies for GMI-1687 completed; submission on track for H1 2022 in sickle cell disease VOC.
- Workforce reduced by 20% in April, mainly early-stage research; executive team added CCO and VP of Tech Ops.
- R&D expenses $9.6M (down from $11.1M); G&A $5.1M (up from $4.2M); no revenue recognized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837022006206/0001558370-22-006206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837022006206/glyc-20220428x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-006206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer